Photo from archive.org
A biomarker analysis involving the largest dataset of its kind finds that tumor mutational burden and T cell-inflamed gene expression profile can independently predict a patient's response to pembrolizumab. However,… Click to show full abstract
A biomarker analysis involving the largest dataset of its kind finds that tumor mutational burden and T cell-inflamed gene expression profile can independently predict a patient's response to pembrolizumab. However, joint consideration of both biomarkers offers the greatest clinical utility and identifies patterns of underlying, targetable biology.
Keywords:
biomarkers immunotherapy;
biology;
combining biomarkers
Journal Title: Cancer discovery
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!